Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy.

IF 2.6 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Prostate Pub Date : 2024-09-27 DOI:10.1002/pros.24801

Michal Jirásko, Roman Viták, Ladislav Pecen, Andrea Pinkeová, Jan Tkáč, Tomáš Bertók, Natalie Bergman, Radek Kučera

{"title":"Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy.","authors":"Michal Jirásko, Roman Viták, Ladislav Pecen, Andrea Pinkeová, Jan Tkáč, Tomáš Bertók, Natalie Bergman, Radek Kučera","doi":"10.1002/pros.24801","DOIUrl":null,"url":null,"abstract":"Background: The medication used to treat benign prostate hyperplasia (BPH), a common condition in men over 50 years of age, can alter the levels of biomarkers used in prostate cancer detection. Commonly used medications for BPH include alpha-blockers, 5-alpha reductase inhibitors (5-ARIs), and muscarinic antagonists. We studied the impact of these drugs on total prostate-specific antigen (tPSA), free PSA (fPSA), [-2]proPSA, fPSA/tPSA ratio, and the Prostate Health Index (PHI), as well as novel potential biomarkers in the form of glycan composition of fPSA.Patients and methods: Serum samples were collected from 564 males with BPH, with a mean age of 68.5 years. The samples were used to measure levels of tPSA, fPSA, and [-2]proPSA. The fPSA/tPSA and PHI were then calculated. The glycan composition of fPSA was analyzed using lectin-based glycoprofiling. Pharmacotherapy data was collected from the patients' medical records.Results: Alpha-blocker monotherapy was associated with higher fPSA and fPSA/tPSA ratio, and decreased PHI. Levels of tPSA were not impacted. Alpha-blocker and 5-ARI dual therapy was associated with reduced levels of fPSA, [-2]proPSA, and PHI. Therapy combining alpha-blockers and antimuscarinic agents did not significantly influence biomarker levels apart from an increase in a Maackia amurensis lectin-recognized glycan originating in fPSA.Conclusion: BPH pharmacotherapy notably affects prostate cancer biomarkers. Recognizing the impact of pharmacotherapy is crucial for achieving an accurate diagnosis of prostate cancer and for planning treatment.","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pros.24801","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The medication used to treat benign prostate hyperplasia (BPH), a common condition in men over 50 years of age, can alter the levels of biomarkers used in prostate cancer detection. Commonly used medications for BPH include alpha-blockers, 5-alpha reductase inhibitors (5-ARIs), and muscarinic antagonists. We studied the impact of these drugs on total prostate-specific antigen (tPSA), free PSA (fPSA), [-2]proPSA, fPSA/tPSA ratio, and the Prostate Health Index (PHI), as well as novel potential biomarkers in the form of glycan composition of fPSA.

Patients and methods: Serum samples were collected from 564 males with BPH, with a mean age of 68.5 years. The samples were used to measure levels of tPSA, fPSA, and [-2]proPSA. The fPSA/tPSA and PHI were then calculated. The glycan composition of fPSA was analyzed using lectin-based glycoprofiling. Pharmacotherapy data was collected from the patients' medical records.

Results: Alpha-blocker monotherapy was associated with higher fPSA and fPSA/tPSA ratio, and decreased PHI. Levels of tPSA were not impacted. Alpha-blocker and 5-ARI dual therapy was associated with reduced levels of fPSA, [-2]proPSA, and PHI. Therapy combining alpha-blockers and antimuscarinic agents did not significantly influence biomarker levels apart from an increase in a Maackia amurensis lectin-recognized glycan originating in fPSA.

Conclusion: BPH pharmacotherapy notably affects prostate cancer biomarkers. Recognizing the impact of pharmacotherapy is crucial for achieving an accurate diagnosis of prostate cancer and for planning treatment.

查看原文本刊更多论文

良性前列腺增生药物治疗患者的前列腺特异性抗原、游离 PSA、[-2]proPSA、fPSA/tPSA 比值、前列腺健康指数和游离 PSA 糖基化模式的血清水平。

背景：良性前列腺增生症（BPH）是 50 岁以上男性的常见病，治疗良性前列腺增生症的药物可改变用于检测前列腺癌的生物标志物的水平。治疗良性前列腺增生症的常用药物包括α-受体阻滞剂、5-α还原酶抑制剂（5-ARIs）和毒蕈碱拮抗剂。我们研究了这些药物对总前列腺特异性抗原（tPSA）、游离 PSA（fPSA）、[-2]proPSA、fPSA/tPSA 比率和前列腺健康指数（PHI）的影响，以及以 fPSA 的糖组成形式存在的新型潜在生物标记物：采集了 564 名患有良性前列腺增生症的男性血清样本，他们的平均年龄为 68.5 岁。这些样本用于测量 tPSA、fPSA 和 [-2]proPSA 的水平。然后计算出 fPSA/tPSA 和 PHI。使用基于凝集素的糖谱分析法分析了 fPSA 的糖组成。从患者的病历中收集了药物治疗数据：结果：α-受体阻滞剂单药治疗与较高的fPSA和fPSA/tPSA比率以及较低的PHI有关。tPSA 的水平未受影响。α-受体阻滞剂和 5-ARI 双联疗法与 fPSA、[-2]proPSA 和 PHI 水平降低有关。结合使用α-受体阻滞剂和抗心绞痛药的疗法，除了增加源自fPSA的Maackia amurensis凝集素识别聚糖外，对生物标志物水平没有显著影响：结论：良性前列腺增生症药物治疗对前列腺癌生物标志物有明显影响。结论：良性前列腺增生症药物治疗对前列腺癌生物标志物影响显著，认识到药物治疗的影响对于准确诊断前列腺癌和制定治疗计划至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate 医学-泌尿学与肾脏学

CiteScore

5.10

自引率

3.60%

发文量

180

审稿时长

1.5 months

期刊介绍： The Prostate is a peer-reviewed journal dedicated to original studies of this organ and the male accessory glands. It serves as an international medium for these studies, presenting comprehensive coverage of clinical, anatomic, embryologic, physiologic, endocrinologic, and biochemical studies.